Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06236295
PHASE2

Investigating the Safety and Efficacy of SHR6508 Injection in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients : A Multicenter, Long-term Clinical Trial

Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

This is a multicenter, single-arm, long-term safety and tolerability trial. A total of 300 subjects with chronic kidney disease on hemodialysis are planned to be enrolled.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

303

Start Date

2024-02-20

Completion Date

2025-11-13

Last Updated

2026-05-20

Healthy Volunteers

No

Interventions

DRUG

SHR6508

SHR6508 will be administered to all the eligible subjects

Locations (1)

Peking University People's Hospital

Beijing, Beijing Municipality, China